Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out carisoprodol and/or meprobamate exposure. For follow-up testing of a presumptive result, Carisoprodol and Meprobamate, Urine, Quantitative (2012219) is preferred.
Qualitative Enzyme Immunoassay/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL)
Breast milk. Pharmaceutical preparation. Specimens exposed to multiple freeze thaw cycles.
Ambient: 1 week: Refrigerated: 1 month: Frozen: 1 month
Screen cutoff concentration 100 ng/mL
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
If the specimen screens positive, then Confirmation/Quantitation by GC-MS (ARUP test code 2012219) will be added to confirm result. Additional charges apply.
80307; if reflexed, add 80369 (Reflexed Alt Code: G0480 )
|Component Test Code*||Component Chart Name||LOINC|
|2012212||Screen, Urine Interpretation||54247-2|
|2012279||Carisoprodol, Urn, Screen||21142-5|
- Carisoprodol and Metabolite
- Soma Compound